Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.

Van Huis, Chad A; Casimiro-Garcia, Agustin; Bigge, Christopher F; Cody, Wayne L; Dudley, Danette A; Filipski, Kevin J; Heemstra, Ronald J; Kohrt, Jeffrey T; Leadley, Robert J; Narasimhan, Lakshmi S; McClanahan, Thomas; Mochalkin, Igor; Pamment, Michael; Peterson, J Thomas; Sahasrabudhe, Vaishali; Schaum, Robert P; Edmunds, Jeremy J

Van Huis, Chad A; Casimiro-Garcia, Agustin; Bigge, Christopher F; Cody, Wayne L; Dudley, Danette A; Filipski, Kevin J; Heemstra, Ronald J; Kohrt, Jeffrey T; Leadley, Robert J; Narasimhan, Lakshmi S; McClanahan, Thomas; Mochalkin, Igor; Pamment, Michael; Peterson, J Thomas; Sahasrabudhe, Vaishali; Schaum, Robert P; Edmunds, Jeremy J.

Affiliation

Van Huis CA; Michigan Laboratories, Ann Arbor Campus, Pfizer Global Research and Development, 2800 Plymouth Road, Ann Arbor, MI 48105, USA.

Bioorg Med Chem ; 17(6): 2501-11, 2009 Mar 15.

Article in En | MEDLINE | ID: mdl-19231206

Subject(s)

Pyrrolidines/pharmacology; Administration, Oral; Crystallography, X-Ray; Half-Life; Humans; Pyrrolidines/administration & dosage; Pyrrolidines/pharmacokinetics

Fulltext

XML

PubMed Links

Search on Google